KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Cash & Equivalents (2017 - 2025)

Elanco Animal Health (ELAN) has disclosed Cash & Equivalents for 9 consecutive years, with $545.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 16.45% to $545.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $545.0 million through Dec 2025, up 16.45% year-over-year, with the annual reading at $545.0 million for FY2025, 16.45% up from the prior year.
  • Cash & Equivalents hit $545.0 million in Q4 2025 for Elanco Animal Health, up from $505.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $638.0 million in Q4 2021 to a low of $318.0 million in Q1 2023.
  • Historically, Cash & Equivalents has averaged $452.0 million across 5 years, with a median of $464.0 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: crashed 58.3% in 2021 and later skyrocketed 41.16% in 2025.
  • Year by year, Cash & Equivalents stood at $638.0 million in 2021, then tumbled by 45.92% to $345.0 million in 2022, then increased by 2.03% to $352.0 million in 2023, then surged by 32.95% to $468.0 million in 2024, then rose by 16.45% to $545.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for ELAN at $545.0 million in Q4 2025, $505.0 million in Q3 2025, and $539.0 million in Q2 2025.